Verrica Pharmaceuticals (NASDAQ:VRCA – Get Rating) was downgraded by investment analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating in a research report issued on Wednesday, The Fly reports.
Several other analysts have also recently commented on VRCA. Zacks Investment Research raised shares of Verrica Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 target price for the company in a research note on Friday, May 13th. Needham & Company LLC decreased their price target on Verrica Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, March 3rd. Brookline Capital Management reaffirmed a “buy” rating on shares of Verrica Pharmaceuticals in a research note on Thursday, March 10th. Brookline Capital Acquisition started coverage on shares of Verrica Pharmaceuticals in a research report on Thursday, March 10th. They issued a “buy” rating and a $20.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Verrica Pharmaceuticals in a research note on Monday, March 7th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $16.89.
Verrica Pharmaceuticals stock opened at $5.56 on Wednesday. Verrica Pharmaceuticals has a fifty-two week low of $5.20 and a fifty-two week high of $14.79. The company has a market capitalization of $153.01 million, a price-to-earnings ratio of -3.56 and a beta of 1.96. The stock has a fifty day moving average of $7.34 and a two-hundred day moving average of $8.52.
Several institutional investors and hedge funds have recently modified their holdings of the business. Morgan Stanley grew its stake in shares of Verrica Pharmaceuticals by 2,540.4% in the second quarter. Morgan Stanley now owns 122,065 shares of the company’s stock valued at $1,380,000 after buying an additional 117,442 shares in the last quarter. Barclays PLC increased its position in shares of Verrica Pharmaceuticals by 213.5% during the third quarter. Barclays PLC now owns 5,352 shares of the company’s stock worth $67,000 after acquiring an additional 3,645 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Verrica Pharmaceuticals by 11.8% in the third quarter. Geode Capital Management LLC now owns 238,069 shares of the company’s stock worth $2,975,000 after acquiring an additional 25,089 shares in the last quarter. HighVista Strategies LLC purchased a new position in shares of Verrica Pharmaceuticals during the 3rd quarter valued at approximately $137,000. Finally, MML Investors Services LLC increased its stake in shares of Verrica Pharmaceuticals by 30.2% in the third quarter. MML Investors Services LLC now owns 44,875 shares of the company’s stock worth $561,000 after buying an additional 10,400 shares during the last quarter. Institutional investors own 34.58% of the company’s stock.
Verrica Pharmaceuticals Company Profile (Get Rating)
Verrica Pharmaceuticals Inc, a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts.
- Get a free copy of the StockNews.com research report on Verrica Pharmaceuticals (VRCA)
- It’s Time to Buy into Planet Fitness Stock
- Investors Can Get 5%-Plus Dividend Yields on These 3 Buys
- Two Retailers, One To Buy And One To Avoid
- Indie Semiconductor Stock is Putting in a Bottom
- 3 Defensive Consumer Stocks Worth Shopping For
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.